Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in steroid- and ciclosporin-dependent nephrotic syndrome in children
2008-004486-26Phase 2Active
- Sponsor
- Istituto Giannina Gaslini
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in Idiopathic nephrotic syndrome (INS), sponsored by Istituto Giannina Gaslini. Primary endpoints: Maintenance of remission and Induction and maintenance of proteinuria remission. Started Mar 2009; status: active.
02
Drugs
rituximab
03
Conditions
Idiopathic nephrotic syndrome (INS)
Beyond the preview
Go deeper on 2008-004486-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004486-26.